𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical evaluation of Parkinson’s disease dementia: association with aging and visual hallucination

✍ Scribed by M. Kitayama; K. Wada-Isoe; K. Nakaso; Y. Irizawa; K. Nakashima

Book ID
109338632
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
629 KB
Volume
116
Category
Article
ISSN
0001-6314

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cognitive correlates of visual hallucina
Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease
✍ Kolbjorn Bronnick; Murat Emre; Sibel Tekin; Siri B. Haugen; Dag Aarsland 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

## Abstract ## Background: There may be a relationship between cognitive impairment and visual hallucinations (VHs) in patients with Parkinson's disease (PD). The objective of this study was to compare the cognitive profile of hallucinating vs. nonhallucinating patients with Parkinson's disease de

Frontal and associative visual areas rel
Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia
✍ Cristina Sanchez-Castaneda; Ramon Rene; Blanca Ramirez-Ruiz; Jaume Campdelacreu; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

## Abstract Visual Hallucinations (VH) are among the core features of Dementia with Lewy Bodies (DLB), but are also very frequent in demented patients with Parkinson's Disease (PDD). The purpose of this study was to investigate the pattern of gray matter and cognitive impairment underlying VH in DL

Effects of rivastigmine in patients with
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
✍ David Burn; Murat Emre; Ian McKeith; Peter Paul De Deyn; Dag Aarsland; Chuanchie 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB 👁 1 views

## Abstract We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24‐week doub